Showing 8141-8150 of 8908 results for "".
- Novel Impetigo Drug on the Horizonhttps://practicaldermatology.com/news/new-impetigo-drug-on-the-horizon/2458518/Medimetriks Pharmaceuticals, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ozenoxacin cream, 1%, a novel, non-fluorinated quinolone for the treatment of impetigo. Medimetriks licensed e
- Restylane Turns 20, Galderma Launches New Syringehttps://practicaldermatology.com/news/restylane-turns-20-galderma-launches-new-syringe/2458533/Happy 20th Restylane®! Galderma is celebrating the 20th anniversary of the Restylane line of products. The line includes Restylane®, Restylane-L®, Restylane® Lyft with Lidocaine and Restylane® Si
- Derm Salaries On The Risehttps://practicaldermatology.com/news/derm-salaries-on-the-rise/2458537/Starting salaries for dermatologists spiked 13 percent in the last 12 months, according to a new report from Merritt Hawkins. The average annual salary for a dermatologist in 2015-2016 was $444,000, with a low of $250,00 and a high of $650
- Solta Medical Launches Consumer Campaign to Empower LGBTQ Communityhttps://practicaldermatology.com/news/solta-medical-launches-consumer-campaign-to-empower-lgbtq-community/2458538/Solta Medical, a division of Valeant Pharmaceuticals North America LLC, is supporting the LGBTQ community through a focused consumer campaign that will help shed one more layer to reveal one’s true self. In addition, Solta Medical was the exclusive medical aesthetic category sponsor of the
- Acne Scars: Survey Highlights the Negative Ways Acne and Acne Scars Can Affect Confidencehttps://practicaldermatology.com/news/acne-scars-survey-highlights-the-negative-ways-acne-and-acne-scars-can-affect-quality-of-life/2458539/Ninety-nine percent people would have more confidence if their acne and acne scars were gone, according to a new survey for Suneva Medical. When it comes to skin issues, respondents feel that acne scars are worse than having acne, eczema or rosacea. Nearly half of adults still have
- Dupilumab with Topical Corticosteroids (TCS) Superior to TCS Alone in Long-term Atopic Dermatitis Studyhttps://practicaldermatology.com/news/dupilumab-with-topical-corticosteroids-tcs-superior-to-tcs-alone-in-long-term-atopic-dermatitis-study/2458541/Treatment with investigational dupilumab in combination with topical corticosteroids (TCS) significantly improved measures of overall disease severity, according to one-year results of the LIBERTY AD CHRONOS study. Reported by Regeneron Pharmaceuticals, Inc. and Sanofi, the phase 3 study involved
- ASDSA Releases New Sun-Safety Model Legislationhttps://practicaldermatology.com/news/asdsa-releases-new-sun-safety-model-legislation/2458548/New model legislation from American Society for Dermatologic Surgery Association (ASDSA) provides state governments with a framework to permit the use of sunscreens in school and camp settings. The
- GlobalMed Technologies Acquires Omnilux Medicalhttps://practicaldermatology.com/news/globalmed-technologies-acquires-omnilux-medical/2458551/GlobalMed Technologies (GMT) has acquired Omnilux Medical, the gold standard for medical and aesthetic Light Emitting Diode (LED) skincare. The asset acquisition includes three Omnilux Medical Systems, the Omnilux Revive2™, Omnilux Blue™ and Omnilux Plus™,
- New Nair Survey Shows Unwanted Body Hair is No Confidence Boosterhttps://practicaldermatology.com/news/new-nair-survey-shows-unwanted-body-hair-is-no-confidence-booster/2458552/Just shy of 80 percent of women are more confident when they do not have unwanted body hair, according to a recent online survey conducted by Harris Poll on behalf of Church & Dwight Co., Inc., the makers of Nair™. Who Wears Short Shorts? Nair for Short Shorts</
- FDA Accepts Allergan's NDA Filing for Oxymetazoline HCI Cream 1.0% for Facial Erythemahttps://practicaldermatology.com/news/fda-accepts-allergans-nda-filing-for-oxymetazoline-hci-cream-10/2458553/The FDA accepted Allergan plc's New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults. Allergan expects the Prescription Drug User Fee